Overview
A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension
Status:
Completed
Completed
Trial end date:
2008-12-01
2008-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine a safe and effective dose of ADX415 for the treatment of hypertension.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Addrenex Pharmaceuticals, Inc.
Criteria
Inclusion Criteria:- Mild to moderate hypertension
- Age 18-75 years, inclusive
Exclusion Criteria:
- Clinically significant illnesses or abnormalities upon evaluation
- Current treatment with 3 or more antihypertensive meds
- Presence of Type I or uncontrolled Type II diabetes
- Presence of alcohol or drug abuse